Home | Articles
Published on:February 2019
Indian Journal of Pharmaceutical Education and Research, 2019; 53(2):325-329
Original Article | doi:10.5530/ijper.53.2.41

Association between Selective Serotonin Reuptake Inhibitors Use and Colorectal Cancer in a Case- Control Study


Authors and affiliation (s):

Shih-Wei Lai1,2, Cheng-Li Lin1,3, Kuan-Fu Liao4,5,*

1Department of Family Medicine, College of Medicine, China Medical University, Taichung, TAIWAN.

2Department of Family Medicine, China Medical University Hospital, Taichung, TAIWAN.

3Department of Management Office for Health Data, China Medical University Hospital, Taichung, TAIWAN.

4Department of Internal Medicine,College of Medicine, Tzu Chi University, Hualien, TAIWAN.

5Department of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, Taichung, TAIWAN.

Abstract:

Objectives: This study’s aim was to investigate whether selective serotonin reuptake inhibitors use was associated with the risk of colorectal cancer. Methods: From the claims data of Taiwan National Health Insurance Program, a retrospective case-control study was conducted to examine 4739 aged 20-84 cases with newly diagnosed colorectal cancer in 2000-2013 and 4739 sex-matched and age-matched controls without colorectal cancer. The prescription history of selective serotonin reuptake inhibitors and other comorbidities were compared between the cases and the matched controls. Results: After adjusting for the potential confounders, the multivariable logistic regression model showed that the odds of selective serotonin reuptake inhibitors use among cases with colorectal cancer were lower than the odds of selective serotonin reuptake inhibitors use among matched controls (adjusted OR 0.77; 95% CI 0.66-0.89). Conclusion: The odds of selective serotonin reuptake inhibitors use among cases with colorectal cancer are lower than among matched controls. This finding indicates that selective serotonin reuptake inhibitors use might be a protective factor against colorectal cancer.

Key words: Case-control study, Colorectal cancer, Selective serotonin reuptake inhibitors, Taiwan National Health Insurance Program.

 




 

Impact Factor

IJPER - An Official Publication of Association of Pharmaceutical Teachers of India is pleased to announce continued growth in the Latest Release of Journal Citation Reports (source: Web of Science Data).

 

Impact Factor® as reported in the 2023 Journal Citation Reports® (Clarivate Analytics, 2023): 0.8

The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmaceutical Education and Research (IJPER) [ISSN-0019-5464] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 1967.

DOI HISTORY

IJPER uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2013 are being assigned DOIs for its permanent URLs